FYB1 is differentially expressed in cutaneous T-cell lymphoma (CTCL) and benign skin biopsy, with FYB significantly upregulated in advanced CTCL; therefore, the differential expression of FYB1 may help predict the risk of this disease [20]. Here, FYB1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.